Report overview
Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race.
This report contains market size and forecasts of Prostate Cancer Diagnostics and Treatment in Global, including the following market information:
Global Prostate Cancer Diagnostics and Treatment Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Prostate Cancer Diagnostics and Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Biological Therapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Prostate Cancer Diagnostics and Treatment include Tolmar, Astellas Pharma, AstraZeneca, Ferring Pharmaceuticals, Johnson & Johnson, Abbott, Sanofi, Ipsen and Novartis, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Prostate Cancer Diagnostics and Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Prostate Cancer Diagnostics and Treatment Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Prostate Cancer Diagnostics and Treatment Market Segment Percentages, by Type, 2022 (%)
Biological Therapy
Chemotherapy
Global Prostate Cancer Diagnostics and Treatment Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Prostate Cancer Diagnostics and Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital
Research Institution
Clinic
Global Prostate Cancer Diagnostics and Treatment Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Prostate Cancer Diagnostics and Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Prostate Cancer Diagnostics and Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Prostate Cancer Diagnostics and Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Tolmar
Astellas Pharma
AstraZeneca
Ferring Pharmaceuticals
Johnson & Johnson
Abbott
Sanofi
Ipsen
Novartis
Bayer
